The highly influential JUPITER trial (2008) considered the impact of rosuvastatin, commonly known as Crestor, on heart disease risk. Over two years, Crestor dramatically decreased cholesterol levels and total cardiovascular events. However, the trial was and remains controversial because it was stopped early (which may have exaggerated its effects), showed a significant increase in diabetes in the treatment group, and involved multiple conflicts of interest.